Investment Rating - The report indicates a positive outlook for the weight loss drug sector within the pharmaceutical and biotechnology industry, suggesting potential acceleration in business development (BD) opportunities [2]. Core Insights - The pharmaceutical and biotechnology sector experienced a slight decline of -0.36% from April 14 to April 18, underperforming compared to the Wind All A index (0.39%) and the CSI 300 index (0.59). The market showed a preference for defensive sectors, with chemical preparations (0.62%), traditional Chinese medicine (0.6%), and offline pharmacies (0.19%) showing minor gains, while blood products (-4.39%), other biological products (-1.78%), and vaccines (-1.49%) saw significant pullbacks [2][7]. - The GLP-1 receptor agonists are expected to catalyze growth in the weight loss drug sector. Notably, Eli Lilly announced positive results from the Phase III ACHIEVE-1 study for its oral drug Orforglipron, which is set to expand the application of GLP-1 drugs. This class of drugs is becoming a focal point for multinational corporations (MNCs) in the metabolic disease space, with domestic companies poised to benefit from rapid innovation and lower R&D costs [2][12]. Market Weekly Review - The pharmaceutical and biotechnology sector's performance from April 14 to April 18 showed a decline of -0.36%, with the market favoring defensive stocks. The top gainers included Shuangcheng Pharmaceutical (56.4%), Kangpeng Technology (56.3%), and Lifang Pharmaceutical (47.1%), while the largest losers were *ST Jiyuan (-50.7%), Hasanlian (-19.1%), and Changyao Holdings (-18.5%) [7][10]. Industry News and Key Company Announcements - On April 17, Eli Lilly announced that its oral GLP-1 receptor agonist Orforglipron achieved positive results in its Phase III study, showing significant reductions in A1C levels and weight loss compared to placebo [12]. - Pfizer terminated the development of its GLP-1 small molecule receptor agonist Danuglipron due to potential liver damage in trial participants [12]. - The report highlights several companies making strides in the industry, including the approval of new indications for Merck's Gardasil 9 HPV vaccine and the progress of various clinical trials for innovative drugs [13][14].

Investment Rating - The report indicates a positive outlook for the consumer sector, suggesting a gradual improvement in the fundamentals of the industry in 2025 [2][4]. Core Viewpoints - The consumer sector has shown a steady recovery, with March retail sales increasing by 5.9% year-on-year, driven by effective policies such as the trade-in program [4]. - The report highlights the importance of government policies in boosting domestic consumption, especially in the context of ongoing trade tensions [4]. - The report emphasizes the potential for growth in various segments, including duty-free, emotional consumption, and tourism-related industries [4]. Summary by Sections Market Weekly Review - The consumer sector experienced an overall increase, with textile and apparel, beauty care, food and beverage, retail, home appliances, and social services showing weekly gains of +1.57%, +0.43%, +0.24%, +0.24%, +0.18%, and +0.14% respectively [4]. - Notable stock performances included Anji Food (+50.00%), Haidar (+17.38%), and Guoguang Chain (+61.10%) [4]. - March retail sales reached a total of 5.9% year-on-year growth, with significant contributions from essential consumer goods [4]. Industry News and Key Company Announcements - The Ministry of Commerce and other departments released a work plan focusing on enhancing service consumption, proposing 48 specific measures to improve service quality and stimulate consumption [4][15]. - Companies like Juewei Foods and Encounter Small Noodles are expanding rapidly, with Encounter Small Noodles achieving a compound annual growth rate of 66.2% from 2022 to 2024 [15][16]. - The report notes that the trade-in policy has significantly boosted sales in home appliances, with over 35.7 million units sold, generating sales of approximately 124.7 billion yuan [4][17].

[Table_Author] 分析师：王俐媛 执业证书号：S1030524080001 电话：0755-83199599 邮箱：wangly1@csco.com.cn 研究助理：徐伊琳 电话：0755-23602217 邮箱：xuyl@csco.com.cn 公司具备证券投资咨询业务资格 证券研究报告 医药生物 G 减肥药 BD 有望加速 [Table_ReportDate] 2025 年 04 月 21 日 [Table_ReportType] 医药生物行业周报（4 月第 3 周） [Table_S 行业ummary 观点：] [Table_Industry] [Table_BaseData] 1) 周度回顾。上周（4 月 14 日-4 月 18 日）医药生物收 跌-0.36%，反弹力度小于 Wind 全 A（0.39%）和沪深 300（0.59%），市场偏好避险板块。从板块来看，贸易 战中波及程度最小的化学制剂（0.62%）、中药（0.6%） 和线下药店（0.19%）小幅收涨，血液制品（-4.39%）、 其他生物制品（-1.78%）和疫苗（-1.49%）回调明显。 从个股来看，重组方向躁动明显，涨幅前三的 ...

[Table_Author] 分析师：陈江月 执业证书：S1030520060001 电话：0755-83199599-9055 邮箱：chenjy@csco.com.cn 宏观 [Table_ReportDate] 2025 年 04 月 14 日 公司具备证券投资咨询业务资格 证券研究报告 关税战短期利空出尽 [Table_ReportType] 宏观周报（4 月第 2 周） [Table_S 核心观点： ummary] 请务必阅读文后重要声明及免责条款 5) 风险提示：基本面恢复不及预期、贸易摩擦超预期升级。 [Table_Industry] [Table_Title] [Table_Report] [Table_BaseData] 经济预测（一致预期） 单位（%） 2409E 24E GDP（Q3E） CPI PPI 工业增加值增速 固定投资增速 社消增速 出口增速 进口增速 M2 增速 社融增速 数据来源：万得资讯 1) 权益：上周市场放量下跌。全周市场围绕关税线索博弈。周一 至周二，在贸易摩擦升级预期下，流动性紧张拖累市场，国内 应对聚焦在维稳市场上，宽基成交放量，市场企稳。周三隔夜 美对中"对等 ...

Investment Rating - The report does not explicitly state an investment rating for the industry [19]. Core Insights - The pharmaceutical and biotechnology sector experienced a decline of 5.61% from April 7 to April 11, underperforming compared to the Wind All A index (-4.31%) and the CSI 300 index (-2.87%) [2][7]. - Blood products (4.06%) and offline pharmacies (1.81%) were the leading sub-sectors, while medical research outsourcing (-16.04%), in vitro diagnostics (-8.28%), and pharmaceutical distribution (-6.4%) faced the largest declines [2][8]. - Recent policies in Beijing and Shenzhen aim to support the innovation of drugs and medical devices, enhancing clinical research efficiency and accelerating the approval process for innovative products [2][11]. - The FDA announced a shift towards non-clinical evaluation methods, moving away from animal testing for monoclonal antibodies and other drugs, promoting the use of AI-based toxicity models and organoid testing [2][12]. Summary by Sections Market Weekly Review - The pharmaceutical and biotechnology sector saw a weekly decline of 5.61%, with blood products and offline pharmacies showing positive growth [7]. - The top three gainers were Yirui Technology (20.5%), Yipinhong (17.0%), and Yong'an Pharmaceutical (13.9%), while the largest decliners included Rundu Co., Ltd. (-27.8%), Duorui Pharmaceutical (-27.2%), and Boteng Co., Ltd. (-22.2%) [10]. Industry News and Key Company Announcements Important Industry Events - The report highlights significant policy changes aimed at fostering the development of innovative drugs and medical devices in major cities [11][12]. - The approval of a gene therapy for hemophilia B by Xinnian Pharmaceutical marks a milestone as the first domestic gene therapy for this condition [11][13]. Company Announcements - ADC company Ying'en Bio completed its IPO, raising over $200 million [15]. - Hongchang Bio presented promising results for its innovative drug Telitacicept at a neurology conference, showing significant improvement in myasthenia gravis patients [15]. - Heng Rui Pharmaceutical announced a licensing agreement with Merck KGaA for its GnRH receptor antagonist, SHR7280, with an upfront payment of €15 million [15][16].

[Table_ReportDate] 2025 年 04 月 14 日 [Table_Author] 分析师：李时樟 执业证书：S1030522060001 电话：18065826333 邮箱：lisz@csco.com.cn 分析师：罗晴 执业证书：S1030524110001 电话：13603091122 邮箱：luoqing@csco.com.cn 公司具备证券投资咨询业务资格 TMT [Table_Title] "对等关税"下看好国产化替代加速 证券研究报告 1) 周度市场回顾。TMT 板块内一级行业上周（4/07-4/11）涨跌 幅为：电子（-3.89%）、计算机（-5.79%）、传媒（-6.78%）、 通信（-7.67%），板块整体跑输沪深 300（-2.87%）。TMT 板 块内涨幅靠前的三级子行业分别为模拟芯片设计（6.04%）、 半导体设备（2.23%），跌幅靠前的三级子行业分别为通信网 络设备及器件（-11.74%）、印制电路板（-10.16%）、营销代 理（-10.13%）。细分到个股来看，电子周涨幅前三的标的分 别为圣邦股份（24.65%）、纳芯微（21.05%）、思瑞浦（15.65% ...

Group 1: Macroeconomic Overview - The market experienced a significant decline last week, with the Shanghai Composite Index dropping by 3.11% and the Shenzhen Component Index falling by 5.13%[9] - The overall trading volume reached 16,124 billion CNY, an increase of 4,756 billion CNY week-on-week[9] - The U.S. imposed a 125% tariff on China, leading to a reciprocal response from China, which has largely priced in the tariff impacts[9] Group 2: Economic Indicators - March CPI showed a year-on-year decrease of 0.1%, while PPI fell by 2.5% year-on-year, indicating ongoing deflationary pressures[10] - The core CPI for Q1 was 0.1 percentage points higher than historical averages, suggesting a mild improvement in consumer demand[11] - The need for supply and demand policies is emphasized to stabilize industrial prices and facilitate internal circulation[11] Group 3: Fixed Income Market - Last week, bond yields generally declined, with the 10-year government bond yield falling within the range of 1.65% to 1.75%[9] - The market anticipates incremental domestic policies in response to the tariff situation, which may lead to increased short-term volatility[9] Group 4: International Market Dynamics - U.S. stock markets rebounded, with the Dow Jones increasing by 4.95% and the S&P 500 by 5.7% due to tariff negotiations[9] - The U.S. dollar index fell by 3.04%, while the offshore RMB appreciated against the dollar, reflecting market adjustments to tariff changes[9]

Investment Rating - The report does not explicitly state an investment rating for the industry [19] Core Insights - The pharmaceutical and biotechnology sector experienced a decline of 5.61% from April 7 to April 11, underperforming compared to the Wind All A index (-4.31%) and the CSI 300 index (-2.87%) [2][7] - Blood products (4.06%) and offline pharmacies (1.81%) were the leading sub-sectors, while medical research outsourcing (-16.04%), in vitro diagnostics (-8.28%), and pharmaceutical distribution (-6.4%) faced significant declines [2][7] - Recent policies in Beijing and Shenzhen aim to support the innovation of drugs and medical devices, enhancing clinical research efficiency and expanding the production and circulation of innovative medicines [2][11] - The FDA announced a shift towards non-clinical evaluation methods, encouraging the use of AI-based toxicity models and organoid testing data in drug applications, marking a new era in drug development [2][12] Summary by Sections Market Weekly Review - The pharmaceutical and biotechnology sector fell by 5.61%, with blood products and offline pharmacies showing gains, while medical research outsourcing and in vitro diagnostics saw the largest declines [7][8] Industry News and Key Company Announcements - Significant events include the approval of a gene therapy for hemophilia B by Xinnian Pharmaceutical and new supportive measures for innovative drugs and medical devices in Beijing and Shenzhen [11][12] - The FDA's new approach aims to replace animal testing with more relevant human-related methods, potentially reducing costs and improving drug safety [12] - Notable company announcements include the completion of a public offering by Ying'en Biotechnology and the approval of various drugs and medical devices by several companies [15][16][17]

装备制造 [Table_ReportDate] 2025 年 4 月 14 日 [T分析师： able_Author 赵晓闯] 电话：0755-83199599 邮箱：zhaoxc@csco.com.cn 分析师：杨贵洲 执业证书号：S1030524060001 电话：0755-83199599 邮箱：yanggz1@csco.com.cn 研究助理：董李延楠 电话：0755-83199599 邮箱：donglyn@csco.com.cn 公司具备证券投资咨询业务资格 执业证书号：S1030511010004 证券研究报告 3 月挖掘机销量保持较快增长 [Table_ReportType]装备制造行业周报（4 月第 2 周） [Table_S 市场行情回顾： ummary] 上周（4 月 7 日-4 月 11 日）机械设备、电力设备及汽车行业 指数涨跌幅分别为-6.78%、-8.09%及-5.51%，在 31 个申万一 级行业中排名分别为第 29、31、21 位；同期沪深 300 涨跌幅 为-2.87%。装备制造领域是出口重点行业，市场表现受贸易战 影响而落后于大市。 行业观点： 请务必阅读文后重要声明及免责 ...

Investment Rating - The report maintains a positive outlook on the domestic consumption electronics industry chain, suggesting a focus on companies related to this sector due to the resilience expected under the "reciprocal tariffs" policy [3]. Core Viewpoints - The report highlights that electronic products are a major category in China's exports to the US, with a total export scale of USD 125.8 billion in 2024, accounting for 24% of total exports to the US [3]. - It emphasizes the acceleration of domestic substitution due to increased tariffs, with a recommendation to focus on domestic companies in sectors significantly impacted by import tariffs, such as analog chips, CPUs, and semiconductor equipment [3]. - The report notes that the import tariff rate on all goods from the US has risen to 125%, enhancing the cost advantage of domestic products [3]. Summary by Sections Market Weekly Review - The TMT sector experienced declines across major industries, with electronics down 3.89%, computers down 5.79%, media down 6.78%, and communications down 7.67%, underperforming the CSI 300 index which fell 2.87% [3]. - The top-performing sub-industries included analog chip design (up 6.04%) and semiconductor equipment (up 2.23%), while the worst performers were communication network equipment and devices (down 11.74%) and printed circuit boards (down 10.16%) [3]. Industry News and Key Company Announcements - Significant events in the industry include the Siemens Data Center Ecosystem Conference and the 13th China Electronic Information Expo [16]. - The report mentions that global AI IT investment is projected to reach USD 315.8 billion in 2024, with a compound annual growth rate (CAGR) of 32.9% expected until 2028 [26]. - It also notes that the global generative AI market is anticipated to grow at a CAGR of 63.8%, reaching USD 284.2 billion by 2028, representing 35% of the total AI market investment [26].